Condition
Trained Immunity
Total Trials
4
Recruiting
0
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (1)
P 4 (2)
Trial Status
Completed2
Unknown1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05766345Phase 4Active Not RecruitingPrimary
BCG-induced Epigenetic Modifications in the NEXT Generation
NCT05790499Not ApplicableUnknown
LDL-c Level Variability and Trained Immunity
NCT03400878Phase 4Completed
Comparing Morbidity and Mortality Effects of Two Different Strains of BCG
NCT02114255Phase 2Completed
Effects of BCG on Influenza Induced Immune Response
Showing all 4 trials